secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001558370-25-000117
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iRadimed Q4 2024 revenue range $19.2-$19.4M, record; full-year revenue $73.1-$73.3M, up 11-12% YoY
--------------------------------------------------------------------------------

- Q4 2024 revenue ~$19.2M-$19.4M, a record; YoY growth 10-11%, sequential growth 5-6%.
- Full-year 2024 revenue ~$73.1M-$73.3M vs $65.6M in 2023, YoY growth 11-12%.
- Orders booked in Q4 exceeded shipments, building robust backlog for 2025.
- CEO Roger Susi cites increasing demand expected to continue through 2025.
- Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000155837025000117/0001558370-25-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000155837025000117/irmd-20250110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer